Angelina S Hwang, Jacob A Kechter, Xing Li, Alysia Hughes, Kevin J Severson, Blake Boudreaux, Puneet Bhullar, Shams Nassir, Miranda Yousif, Nan Zhang, Richard J Butterfield, Steven Nelson, Xianying Xing, Lam C Tsoi, Samantha Zunich, Aleksandar Sekulic, Mark Pittelkow, Johann E Gudjonsson, Aaron Mangold
Necrobiosis Lipoidica (NL) is a rare granulomatous disease. There are few effective treatments for NL. We sought to investigate the efficacy and safety of the JAK 1/2 inhibitor, ruxolitnib, in the treatment of NL and identify biomarkers associated with disease and treatment response. We conducted an open-label, phase 2 study of ruxolitinib in 12 patients with NL. We performed transcriptomic analysis of tissue samples pre- and post-treatment. At week 12, the mean NL lesion score decreased by 58.2% (SD 28.7%, P=0...
February 26, 2024: Journal of Investigative Dermatology